Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind”

December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind.” The report can be accessed here.

Vivos is a commercial stage medtech device and services company focused on the treatment of dentofacial abnormalities and associated conditions, including obstructive sleep apnea (OSA), snoring, and temporomandibular joint dysfunction (TMD). The company’s proprietary Complete Airway Repositioning and/or Expansion (CARE) devices are the first and only oral appliances with FDA 510(K) clearance to treat moderate to severe OSA in adults and children, in addition to the initial clearance for mild to moderate OSA in adults. Vivos provides an end- to-end therapeutic solution for OSA, including diagnostic and screening tools, oral appliances, myofunctional therapy, clinical treatment, continuing education, and practice management software utilizing the Vivos Method proprietary protocol. The product portfolio also includes Guided Growth and Development oral appliances for proper mouth and jaw development in children and Lifeline oral appliances for mild to moderate OSA by mandibular advancement or TMD symptoms, teeth grinding, migraine headaches, and facial muscle pain. Vivos’ oral appliances have treated more than 47,000 patients by more than 2,000 Vivos-trained dentists.

Vivos recently received FDA clearance for the DNA appliance, its flagship CARE device, in pediatric patients aged 6-17 years with moderate/severe OSA. The company believes the FDA clearance is the first ever granted for a medical device therapy in this young OSA population. As the DNA oral appliance is the only non-surgical FDA-cleared medical device approved for pediatric OSA, with clear clinical study-based evidence, Vivos is in a position to provide first- line therapy to the estimated 10.1 million US children (ages 6-17), potentially doubling the market opportunity for the proprietary CARE devices. Of the 47,000 patients treated with Vivos’ oral appliances, more than 20,000 children have used Vivos’ Guided Growth and Development appliances, highlighting the company’s experience in the pediatric space.

About Water Tower Research

Water Tower Research is modernizing Investor Relations through research-driven communications and Investor Engagement. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.